NCT02737462View on ClinicalTrials.gov

Phase 1/2 Study of CG200745 PPA for Myelodysplastic Syndrome

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

December 31, 2022

Study Completion Date

December 31, 2023

Conditions
Myelodysplastic Syndrome
Interventions
DRUG

CG200745 PPA

CG200745 PPA intravenously daily for first 5 consecutive days per cycle (4 weeks)

Trial Locations (1)

Unknown

Asan Medical Center, Samsung Medical Center, Seoul National University Hospital, Seoul

Sponsors
All Listed Sponsors
lead

CrystalGenomics, Inc.

INDUSTRY